Market Access/ News/ News ExeVir ready for clinic with variant-targeting llama antibody Richard Staines COVID-19, Eli Lilly, ExeVir, llama, R&D, Regeneron 0 Comment Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – Share X ExeVir ready for clinic with variant-targeting llama antibody https://pharmaphorum.com/news/exevirs-ready-for-clinic-with-covid-variant-busting-llama-antibody/
News/ News/ R&D/ Top stories Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out Richard Staines Ablynx, coronavirus, COVID-19, ExeVir, Sanofi 0 Comment Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after Share X Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out https://pharmaphorum.com/news/can-llama-antibodies-beat-covid-19-belgiums-exevir-raises-23m-euros-to-find-out/
COVID-19, Eli Lilly, ExeVir, llama, R&D, Regeneron
0 Comment
